US20230019418A1 - Aqueous solution of burlulipase comprising calcium ions - Google Patents
Aqueous solution of burlulipase comprising calcium ions Download PDFInfo
- Publication number
- US20230019418A1 US20230019418A1 US17/868,079 US202217868079A US2023019418A1 US 20230019418 A1 US20230019418 A1 US 20230019418A1 US 202217868079 A US202217868079 A US 202217868079A US 2023019418 A1 US2023019418 A1 US 2023019418A1
- Authority
- US
- United States
- Prior art keywords
- aqueous solution
- burlulipase
- calcium ions
- concentration
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229950002931 burlulipase Drugs 0.000 title claims abstract description 70
- 239000007864 aqueous solution Substances 0.000 title claims abstract description 52
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 title claims abstract description 34
- 229910001424 calcium ion Inorganic materials 0.000 title claims abstract description 34
- 239000000243 solution Substances 0.000 claims abstract description 52
- 238000000034 method Methods 0.000 claims abstract description 36
- 201000007089 exocrine pancreatic insufficiency Diseases 0.000 claims abstract description 10
- 201000003883 Cystic fibrosis Diseases 0.000 claims abstract description 5
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 43
- 229940127557 pharmaceutical product Drugs 0.000 claims description 38
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 17
- 239000001110 calcium chloride Substances 0.000 claims description 17
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 17
- 239000012535 impurity Substances 0.000 claims description 12
- 230000008569 process Effects 0.000 claims description 9
- 238000003860 storage Methods 0.000 claims description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 150000002632 lipids Chemical class 0.000 claims description 4
- 230000000813 microbial effect Effects 0.000 claims description 4
- 230000003612 virological effect Effects 0.000 claims description 4
- 208000035467 Pancreatic insufficiency Diseases 0.000 claims description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 3
- 238000004806 packaging method and process Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract 5
- 230000000694 effects Effects 0.000 description 21
- 102000004169 proteins and genes Human genes 0.000 description 19
- 108090000623 proteins and genes Proteins 0.000 description 19
- 239000013543 active substance Substances 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 239000000126 substance Substances 0.000 description 10
- 108010019160 Pancreatin Proteins 0.000 description 9
- 229940055695 pancreatin Drugs 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 108090001060 Lipase Proteins 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 102000004882 Lipase Human genes 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000004367 Lipase Substances 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 239000002050 international nonproprietary name Substances 0.000 description 4
- 235000019421 lipase Nutrition 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 210000000496 pancreas Anatomy 0.000 description 4
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 108010067035 Pancrelipase Proteins 0.000 description 3
- 241000282887 Suidae Species 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 230000002366 lipolytic effect Effects 0.000 description 3
- 239000006174 pH buffer Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- PNNNRSAQSRJVSB-ARQDHWQXSA-N (2s,3s,4s,5r)-2,3,4,5-tetrahydroxyhexanal Chemical compound C[C@@H](O)[C@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-ARQDHWQXSA-N 0.000 description 2
- 241000134107 Burkholderia plantarii Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 102000002265 Human Growth Hormone Human genes 0.000 description 2
- 108010000521 Human Growth Hormone Proteins 0.000 description 2
- 239000000854 Human Growth Hormone Substances 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 238000000113 differential scanning calorimetry Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229940040461 lipase Drugs 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000001542 size-exclusion chromatography Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241001453380 Burkholderia Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000005701 Calcium-Binding Proteins Human genes 0.000 description 1
- 108010045403 Calcium-Binding Proteins Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102100031415 Hepatic triacylglycerol lipase Human genes 0.000 description 1
- 101001134456 Homo sapiens Pancreatic triacylglycerol lipase Proteins 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000019280 Pancreatic lipases Human genes 0.000 description 1
- 108050006759 Pancreatic lipases Proteins 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000425573 Talanes Species 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229910001854 alkali hydroxide Inorganic materials 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 208000005881 bovine spongiform encephalopathy Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 238000007707 calorimetry Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 238000005238 degreasing Methods 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000012395 formulation development Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 102000046759 human PNLIP Human genes 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019626 lipase activity Nutrition 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229940116369 pancreatic lipase Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 230000008646 thermal stress Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/18—Carboxylic ester hydrolases (3.1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/01—Carboxylic ester hydrolases (3.1.1)
- C12Y301/01003—Triacylglycerol lipase (3.1.1.3)
Definitions
- the present invention relates to an aqueous solution comprising burlulipase, which is characterized in that it contains calcium ions.
- it also relates to corresponding pharmaceutical products.
- Such pharmaceutical products are suitable for the treatment of exocrine pancreatic insufficiency.
- These pharmaceutical products are particularly suitable for the treatment of patients having mucoviscidosis and in pediatrics.
- a further aspect of the present invention relates to solutions and pharmaceutical products, as mentioned above, packaged in containers, which are containers produced by means of the blow-fill-seal process, and to methods for producing such packaged solutions and pharmaceutical products.
- pancreatin On the one hand, large quantities (large masses) of pancreatin must be taken, which impairs compliance.
- the pancreatin contains varying amounts of impurities, which also depend on the raw material.
- pancreatin contains residual quantities of viral and microbial impurities originating from the raw material.
- biological impurities originating from mammals in pharmaceutical products are seen increasingly critical by the approval authorities. Therefore, approvals of pharmaceutical products produced from animal or human tissue are increasingly problematic.
- pancreatin cannot be administered in a liquid form, which represents an obstacle for use in pediatrics.
- EP 2 391 382 B1 describes pharmaceutical preparations containing bacterial lipases in aqueous solutions. These are suitable for the treatment of pancreatic insufficiency, in particular in mucoviscidosis, and for the treatment of children as well as for the treatment of pancreatitis.
- the enzyme burlulipase was obtained from Burkholderia plantarii (triacylglycerol lipase; EC-3.1.1.3) by expression, and its suitability for enzyme substitution in exocrine pancreatic insufficiency has been verified. Burlulipase is suitable for the therapy of exocrine pancreatic insufficiency, but can only be stored and administered under certain conditions.
- solutions of burlulipase can only be stored for a prolonged period of time in a refrigerated form without reduction of its activity. Therefore, it is difficult to provide solutions of burlulipase for the treatment of exocrine pancreatic insufficiency, which are long-term stable at room temperature and therefore can be stored at room temperature.
- the solutions should have a higher storage capability at temperatures of more than 10° C., and particularly preferably, the solutions should have a higher storage capability at 15 to 35° C.
- a further object of the present invention is to provide preparations of burlulipase, which can be produced as easily as possible and are as sterile as possible and which can be precisely dosed and can be easily taken.
- the active substance burlulipase is initially present in a quality, which still contains considerable quantities of the carbohydrate 6-deoxy-talane as an accompanying substance, a mixture of polymers and oligomers of 6-deoxy-talose (see Zähringer, U. et al., “Structure of a new 6-deoxy- ⁇ -D-talan from Burkholderia ( Pseudomonas ) plantarii strain DSM 6535, which is different from the 0-chain of the lipopolysaccharide”, Carbohydrate Research 300 (1997), 143-151. Normally, 6-deoxy-talane is analytically detected in the form of its monomer 6-deoxy-talose.
- the present aqueous solutions as described herein preferably contain at least 10% by weight of water, more preferably at least 30% by weight of water and even more preferably at least 40% by weight of water, particularly preferably at least 50% by weight of water, and most preferably at least 70% by weight of water. It is also preferred that the aqueous solutions according to the invention contain less than 30% by weight, preferably less than 10% by weight, more preferably less than 5% by weight and most preferably less than 1% by weight of alcohols with a carbon number of 6 or less.
- burlulipase is present in the solutions according to the invention in a mass concentration of 0.1 to 35 mg of protein/ml.
- a mass concentration of 0.1 to 35 mg of protein/ml is used below for concentrations, these respectively are mass concentrations.
- mass concentrations are mass concentrations outside this range.
- the burlulipase is present in a concentration of 0.5 to 30 mg of protein/ml, more preferably in a concentration of 1 to 25 mg of protein/ml, and most preferably in a concentration of 3 to 20 mg of protein/ml.
- a concentration of 0.1 to 35 mg of protein/ml is easy to prepare and normally is physiologically active enough to be used in the treatment of a patient.
- an aqueous solution according to the invention as described herein which contains calcium chloride in the substance concentrations indicated above for calcium ions.
- the reasons for this are as described above for the use of calcium chloride and the amounts of calcium ions.
- acids and bases can be added to the aqueous solutions according to the invention as described herein in a simple manner.
- the choice of acids and bases is not particularly limited. All possible acids and bases can be used for this purpose.
- Acids with a low pKa value such as hydrochloric acid or sulfuric acid, and bases with a high pKa value, such as, for example, alkali hydroxides, are particularly suitable.
- pH buffers are also preferably used in order to adjust the pH appropriately. Such pH buffers ensure that the pH value is maintained permanently and prevent fluctuations in the acid and base contents of the raw materials used to prepare the solutions according to the invention from influencing the pH of the solutions according to the invention.
- the aqueous solutions according to the invention can contain pharmaceutically acceptable excipients in customary amounts, which are known to the person skilled in the art from prior art.
- the aqueous solutions according to the invention can contain emulsifiers, solubilizers, flavors, odorants and colorants, solvents, sugars (glucose, lactose), preferably non-reducing sugars (trehalose, saccharose), alcohols, sugar alcohols (e.g., mannitol, sorbitol), lipids, amino acids, salts, electrolytes, antioxidants, preservatives and anti-microbially active substances.
- Pancreatin can only be provided as a solid and must be taken in large quantities, large dosage forms and/or in a large number of dosage forms (e.g., tablets or capsules) every day. This is often difficult, especially for children.
- the present aqueous solutions can be administered as beverages or in beverages accompanying meals, are therefore also easily accessible for children and also allow for high compliance in pediatrics.
- Containers produced by the blow-fill-seal processes are plastic containers, which are opened by simply tearing them open or cutting them open or the like.
- the pharmaceutical product or the solution is available without great effort and can also be easily handled by laypersons, in particular patients.
- these containers have the advantage that the pharmaceutical products are filled in in portions and permit accurate dosing.
- Containers produced by the blow-fill-seal processes are therefore ideally suited for administration of liquid pharmaceutical products for ingestion by the patients themselves. This in particular applies to indications in pediatrics.
- Microcalorimetry measurement of the solution of burlulipase in water exhibited a peak at about 73° C. This shows that burlulipase unfolds in an aqueous solution at about 73° C.
- the corresponding curve for the calcium chloride-containing solution indicated an unfolding temperature of about 88° C., i.e. about 15° C. higher. This is a clear indication that calcium chloride could stabilize burlulipase.
- the burlulipase solution which only contains 1% by weight of 6-deoxy-talane, is more stable than the comparative solution with 30% by weight. Therefore, using burlulipase with a low 6-deoxy-talane content in pharmaceutical products is appropriate.
Abstract
Description
- The present application is a continuation application of U.S. patent application Ser. No. 16/490,550, filed on Sep. 1, 2019, the disclosure of which is hereby incorporated by reference herein in its entirety.
- The present invention relates to an aqueous solution comprising burlulipase, which is characterized in that it contains calcium ions. In particular, it also relates to corresponding pharmaceutical products. Such pharmaceutical products are suitable for the treatment of exocrine pancreatic insufficiency. These pharmaceutical products are particularly suitable for the treatment of patients having mucoviscidosis and in pediatrics. A further aspect of the present invention relates to solutions and pharmaceutical products, as mentioned above, packaged in containers, which are containers produced by means of the blow-fill-seal process, and to methods for producing such packaged solutions and pharmaceutical products.
- Exocrine pancreatic insufficiency is a disease, in which the pancreas does not provide any digestive enzymes or not in sufficient quantities. For treatment, an enzyme substitution has long been used, in which a product obtained from the pancreases of pigs is administered in the form of so-called “pancreatin”. This is a solid produced in a multistage process, which comprises the degreasing of pancreases from pigs and the removal of fibers therefrom. Pancreatin is a brown powder, which, in addition to the desired main constituents lipase, protease and amylase, also contains a large number of residues from the pancreases of the pigs. This treatment is very successful and usually without serious side effects. However, it has two disadvantages. On the one hand, large quantities (large masses) of pancreatin must be taken, which impairs compliance. On the other hand, the pancreatin contains varying amounts of impurities, which also depend on the raw material. In particular, pancreatin contains residual quantities of viral and microbial impurities originating from the raw material. In view of the discussion about bovine spongiform encephalopathy, biological impurities originating from mammals in pharmaceutical products are seen increasingly critical by the approval authorities. Therefore, approvals of pharmaceutical products produced from animal or human tissue are increasingly problematic. Furthermore, pancreatin cannot be administered in a liquid form, which represents an obstacle for use in pediatrics.
- EP 2 391 382 B1 describes pharmaceutical preparations containing bacterial lipases in aqueous solutions. These are suitable for the treatment of pancreatic insufficiency, in particular in mucoviscidosis, and for the treatment of children as well as for the treatment of pancreatitis. Among other things, the enzyme burlulipase was obtained from Burkholderia plantarii (triacylglycerol lipase; EC-3.1.1.3) by expression, and its suitability for enzyme substitution in exocrine pancreatic insufficiency has been verified. Burlulipase is suitable for the therapy of exocrine pancreatic insufficiency, but can only be stored and administered under certain conditions. In particular, solutions of burlulipase can only be stored for a prolonged period of time in a refrigerated form without reduction of its activity. Therefore, it is difficult to provide solutions of burlulipase for the treatment of exocrine pancreatic insufficiency, which are long-term stable at room temperature and therefore can be stored at room temperature.
- It is known that various reagents, such as buffer systems, sugars, metal ions, emulsifiers, etc. can influence the stability of proteins and in particular of enzymes. For pancreatic lipase, an influence of calcium ions on the activity was verified (see Kimura, H. et al., “Activation of Human Pancreatic Lipase Activity by Calcium and Bile Salts”, J. Biochem. 92, 243-251 (1982)), and for the human growth hormone, an influence of calcium ions on stability was verified (see Saboury, A. A. et al., “Effect of calcium binding on the structure and stability of human growth hormone”, International Journal of Biological Macromolecules 36 (2005) 305-309).
- In the article by Ahmed M. K. Youssef and Gerhard Winter, “A critical evaluation of microcalorimetry as a predictive tool for long term stability of liquid protein formulations: Granulocyte Colony Stimulating Factor (GCSF)”, European Journal of Pharmaceutics and Biopharmaceutics 84 (2013), pages 145 to 155, micro-differential scanning calorimetry (dynamic micro-differential calorimetry) is established as a method for determining changes in the tertiary structure of proteins, in particular enzymes, in solutions. Therefore, this method is suitable for determining the stability of enzymes in solutions. For this reason, this analytical method is used in the present application. Hereinafter, micro-differential scanning calorimetry is also referred to as microcalorimetry or abbreviated by μDSC.
- It was an object of the present invention to provide solutions of burlulipase which have an increased thermal stability compared to solutions of burlulipase in pure water. In particular, the solutions should have a higher storage capability at temperatures of more than 10° C., and particularly preferably, the solutions should have a higher storage capability at 15 to 35° C. In particular, it is also an object of the present invention to provide burlulipase preparations which have sufficient thermal stability, which allows them to be taken even after sequential storage. A further object of the present invention is to provide preparations of burlulipase, which can be produced as easily as possible and are as sterile as possible and which can be precisely dosed and can be easily taken.
- The International Nonproprietary Name (INN) as a name for a medicinal active substance in the public domain is assigned by the World Health Organization (WHO). As such, the INN name burlulipase initially refers exclusively to the lipolytically active protein as a pure active substance. In the real production of pharmaceutical active substances, however, this purest state represents a theoretical ideal, since the active substances, even though only in traces, still always contain accompanying substances and impurities. Thus, in addition to the active substance burlulipase (INN), the active ingredient burlulipase, too, inevitably contains accompanying substances and impurities. Therefore, in terms of the present invention, the term “burlulipase” is to be understood as meaning the different qualities of this active substance. In particular, during the production process, the active substance burlulipase is initially present in a quality, which still contains considerable quantities of the carbohydrate 6-deoxy-talane as an accompanying substance, a mixture of polymers and oligomers of 6-deoxy-talose (see Zähringer, U. et al., “Structure of a new 6-deoxy-α-D-talan from Burkholderia (Pseudomonas) plantarii strain DSM 6535, which is different from the 0-chain of the lipopolysaccharide”, Carbohydrate Research 300 (1997), 143-151. Normally, 6-deoxy-talane is analytically detected in the form of its monomer 6-deoxy-talose. As a result of extensive separation of the 6-deoxy-talane, however, a very pure quality of the active substance burlulipase can also be obtained therefrom, which contains only small quantities of 6-deoxy-talane. In addition to 6-deoxy-talane, both qualities contain small amounts of other accompanying substances and impurities, including, in particular, rhamnolipids as lipopolysaccharides, but also, inter alia, rhamnose and lipids. Therefore, in terms of the present invention, the term “burlulipase” is to be understood as meaning all qualities of this active substance, in particular also the two qualities described above. The present invention relates to a preparation of burlulipase, which is an aqueous solution comprising burlulipase, which is characterized in that it contains calcium ions. Calcium ions have the property that they stabilize solutions of burlulipase in water against thermal stresses. Therefore, aqueous solutions containing burlulipase and calcium ions can be stored longer or at higher temperatures, without the activity loss being increased in comparison to a solution containing no calcium ions. Thereby, the expiration date is extended or the storage temperature can be increased. In that, aqueous solutions containing calcium chloride as described herein are preferred. In that, it is immaterial, whether the calcium chloride has been added as such or whether the calcium ions and chloride ions originate from different sources, as long as the solution contains calcium chloride, i.e. both calcium ions and chloride ions. Calcium chloride is a physiologically compatible form of calcium ions, which does not impair the effect of calcium ions on the burlulipase.
- The present aqueous solutions as described herein preferably contain at least 10% by weight of water, more preferably at least 30% by weight of water and even more preferably at least 40% by weight of water, particularly preferably at least 50% by weight of water, and most preferably at least 70% by weight of water. It is also preferred that the aqueous solutions according to the invention contain less than 30% by weight, preferably less than 10% by weight, more preferably less than 5% by weight and most preferably less than 1% by weight of alcohols with a carbon number of 6 or less.
- Normally, burlulipase is present in the solutions according to the invention in a mass concentration of 0.1 to 35 mg of protein/ml. Where the unit of a mass per volume, such as mg/ml, is used below for concentrations, these respectively are mass concentrations. For special applications, however, it is also possible to use mass concentrations outside this range. Preferably, the burlulipase is present in a concentration of 0.5 to 30 mg of protein/ml, more preferably in a concentration of 1 to 25 mg of protein/ml, and most preferably in a concentration of 3 to 20 mg of protein/ml. A concentration of 0.1 to 35 mg of protein/ml is easy to prepare and normally is physiologically active enough to be used in the treatment of a patient. A concentration of 0.5 to 30 mg of protein/ml is preferred, because at least a concentration of 0.5 mg of protein/ml is often necessary in order to achieve a sufficient dosage, and a concentration of 30 mg of protein/ml in a suitable formulation is stable even at room temperature over a period of at least 6 months. A concentration of 1 to 25 mg of protein/ml is sufficient for most therapies, and normally a concentration of 3 to 20 mg of protein/ml will be adequate. For use in pediatrics, concentrations of 2 to 10 mg of protein/ml are preferred.
- In principle, the aqueous solution according to the invention as described herein can contain any amounts of calcium ions. Calcium ions exhibit a stabilizing effect even in very small quantities. The upper limit is essentially determined by the physiological compatibility of calcium ions. Normally, however, calcium ions are present in a concentration of up to 200 mmol/l, preferably in a concentration of 0.01 to 150 mmol/l. Where the unit of an amount of substance per volume, such as mmol/l, is used below for concentrations, these respectively are concentrations of substance amounts. In this amount, calcium ions are present in sufficient quantity to substantially stabilize all burlulipase molecules, but at the same time are not concentrated to such an extent that they lead to side effects. This in particular applies to the range from 0.1 to 50 mmol/l, which therefore is particularly preferred. High preference is given to an aqueous solution according to the invention as described herein, which contains calcium ions in an amount of 0.5 to 20 mmol/l. Most preferred, however, is an amount of 5 to 30 mmol. These small amounts additionally ensure that the physiologically tolerated amount of calcium chloride is not exceeded.
- Particularly preferred is an aqueous solution according to the invention as described herein, which contains calcium chloride in the substance concentrations indicated above for calcium ions. The reasons for this are as described above for the use of calcium chloride and the amounts of calcium ions.
- Aqueous solutions of burlulipase are normally most stable in a pH range from 4 to 9. Therefore, aqueous solutions according to the invention as described herein are preferred, which have a pH of 4 to 9. More preferred are such aqueous solutions according to the invention, which have a pH of 6 to 8, and particularly preferably of 7 to 8. The aqueous solutions according to the invention are most stable in a pH range from 7.3 to 7.7, and therefore such solutions according to the invention are most preferred, which have a pH of 7.3 to 7.7.
- To adjust the pH value, acids and bases can be added to the aqueous solutions according to the invention as described herein in a simple manner. In that, the choice of acids and bases is not particularly limited. All possible acids and bases can be used for this purpose. Acids with a low pKa value, such as hydrochloric acid or sulfuric acid, and bases with a high pKa value, such as, for example, alkali hydroxides, are particularly suitable. pH buffers are also preferably used in order to adjust the pH appropriately. Such pH buffers ensure that the pH value is maintained permanently and prevent fluctuations in the acid and base contents of the raw materials used to prepare the solutions according to the invention from influencing the pH of the solutions according to the invention.
- Preference is given to tris(hydroxymethyl)aminomethane for use as a constituent of the pH buffer in the aqueous solutions according to the invention. Therefore, an aqueous solution is preferred which contains tris(hydroxymethyl)aminomethane.
- Furthermore, the aqueous solutions according to the invention can contain pharmaceutically acceptable excipients in customary amounts, which are known to the person skilled in the art from prior art. In particular, the aqueous solutions according to the invention can contain emulsifiers, solubilizers, flavors, odorants and colorants, solvents, sugars (glucose, lactose), preferably non-reducing sugars (trehalose, saccharose), alcohols, sugar alcohols (e.g., mannitol, sorbitol), lipids, amino acids, salts, electrolytes, antioxidants, preservatives and anti-microbially active substances. Other suitable excipients can be retrieved, for example, from the “Lexikon der Hilfsstoffe für Pharmazie, Kosmetik and angrenzende Gebiete” (Fiedler, Herbert P.; Vol. 2, 40 OVR Oberschwäbische Verlagsanstalt Ravensburg, 1989). The aqueous solution according to the invention can also contain carrier substances, wherein polyols and especially monosaccharides and polysaccharides are preferred. Particularly suitable excipients are listed, e.g., in the book “Pharmaceutical Formulation Development of Peptides and Proteins”, Second Edition (CRC Press, authors: Lars Hovgaard, Sven Frokjaer, Marco van de Weer), in chapters 8 and 10, among others. Other suitable excipients as well as combinations thereof can be found in numerous publications and patent applications of Wolfgang Frieß, Gerhard Winter, John Carpenter, Michael Pikal, Patrick Garidel and Hanns-Christian Mahler.
- As already described above, the aqueous solution according to the invention of a corresponding quality of the active substance burlulipase, as described herein, can contain considerable amounts of 6-deoxy-talane as an accompanying substance. In these cases, it particularly preferably contains 6-deoxy-talane in an amount of 1 to 60% by weight based on the dried active substance, and most preferably, in these cases, it contains 6-deoxy-talane in an amount of 15 to 40% by weight relative to the dried burlulipase. 6-deoxy-talane, however, also contributes to the thermal instability of burlulipase. Therefore, aqueous solutions according to the invention are preferred, in which 6-deoxy-talane is contained in an amount of 10% by weight or less, more preferably of 2% by weight or less, and particularly preferably of 1% by weight or less, respectively relative to burlulipase.
- Furthermore, the aqueous solution according to the invention as described herein may contain impurities, which result from the preparation process. Burlulipase is normally obtained by expression from Burkholderia plantarii. Most of the impurities can be removed during the purification process. A small portion, however, can also be contained in the product after purification.
- A further aspect of the present invention is a pharmaceutical product comprising an aqueous solution according to the invention as described herein. The major advantage of the aqueous solution according to the invention as described herein is that, compared to lipases obtained from animals, it does not have any viral or microbial impurities. In particular, it contains no viruses, bacteria or prions from animal sources and is therefore to be classified as harmless and free from side effects in this respect.
- The pharmaceutical product according to the invention as described herein preferably is a pharmaceutical product for the treatment of exocrine pancreatic insufficiency. The effect of burlulipase in the treatment of exocrine pancreatic insufficiency is already known, and the pharmaceutical product according to the invention can substitute the pancreatin customarily used in this therapy. In that, the pharmaceutical product according to the invention has the advantage over pancreatin, that it contains no viral or microbial impurities. The pharmaceutical product according to the invention as described herein is particularly suitable for the treatment of pancreatic insufficiency in patients having mucoviscidosis. Furthermore, the pharmaceutical product according to the invention as described herein is suitable for use in pediatrics. Pancreatin can only be provided as a solid and must be taken in large quantities, large dosage forms and/or in a large number of dosage forms (e.g., tablets or capsules) every day. This is often difficult, especially for children. The present aqueous solutions can be administered as beverages or in beverages accompanying meals, are therefore also easily accessible for children and also allow for high compliance in pediatrics.
- Particularly preferably, the pharmaceutical product according to the invention as described herein is intended and suitable for use after sequential storage. In terms of this application, sequential storage shall mean that the pharmaceutical product is first stored in an uninterrupted cooling chain, but can also be kept at room temperature during the time immediately before as well as during the time after a package has been opened, until it has been used up. This is important in order to ensure an adequate supply of the patients with the active substance burlulipase. Without stabilization by calcium ions, the stability of burlulipase is limited. Even though an uninterrupted cooling chain is present at the manufacturer's, in wholesale trade and in pharmacies, it is often difficult for the patient to ensure permanent cooling. Aside from the fact that many patients, especially in poorer countries, do not have any cooling options, it is often difficult for patients to apply the necessary discipline in order to ensure cooling. In particular while travelling or when being away from home all day, this frequently is a problem. This may lead to an undersupply of the patients. This in particular applies since the patient is not able to determine the remaining activity of the burlulipase.
- The pharmaceutical product according to the invention, however, contains a stabilized form of the burlulipase, which makes it possible to also store the pharmaceutical product for a prolonged period outside a cooled location without the activity of the active ingredient decreasing below the activity required to be effective. Depending on the weather, the pharmaceutical product according to the invention can be stored at ambient temperature for up to four weeks or longer, without the activity decreasing too much. Depending on the climate zone, the size of the package can be adapted such that, with appropriate dosing, it is consumed before the activity of the lipase has decreased too much due to thermal deactivation. Therefore, the pharmaceutical product according to the invention can safely be carried along and taken by the patient him/herself, without the risk of incorrect dosing.
- A further aspect of the present invention is an aqueous solution according to the invention as described herein or a pharmaceutical product according to the invention as described herein, wherein the solution or the pharmaceutical product is packaged in a container which has been produced by the blow-fill-seal process.
- A further aspect of the present invention is also a process for producing a packaged aqueous solution as described herein or a packaged pharmaceutical product according to the invention as described herein, wherein the aqueous solution according to the invention or the pharmaceutical product according to the invention is packaged according to the blow-fill-seal process. In that, particular preference is given to a process as described herein comprising the steps of:
-
- providing a polymer
- extruding the polymer through an annular horizontal opening, so that a hanging tube is formed,
- cutting off the tube,
- closing the tube at the lower end,
- inserting the tube into a mold,
- inflating the tube, so that the tube fills the mold and the material of the tube forms the wall of a container,
- filling a solution according to the invention or a pharmaceutical product according to the invention into the container,
- closing the container,
- wherein at least the filling in of the solution or the pharmaceutical product, resp., and the closing of the container take place under sterile conditions. In that, the steps of cutting off the tube, closing the tube at the lower end and inserting the tube into a mold may be undertaken in any order. All other process steps are preferably carried out in the order stated. Particularly preferably all process steps are carried out in the order stated above.
- Containers produced by the blow-fill-seal processes are plastic containers, which are opened by simply tearing them open or cutting them open or the like. Thus, in contrast to glass containers, the pharmaceutical product or the solution is available without great effort and can also be easily handled by laypersons, in particular patients. Thus, contrary to the use of vials, it is not necessary to handle needles and the like. Glass breakage also cannot occur. In comparison to glass bottles, these containers have the advantage that the pharmaceutical products are filled in in portions and permit accurate dosing. Containers produced by the blow-fill-seal processes are therefore ideally suited for administration of liquid pharmaceutical products for ingestion by the patients themselves. This in particular applies to indications in pediatrics.
- Burlulipase was prepared according to Example 1 of EP 0 592 478 B2. This applies to all tests.
- In order to study the effect of various additives on the thermal stability of aqueous solutions of burlulipase, various solutions of burlulipase in water were measured by means of microcalorimetry. Microcalorimetry is an analytical method, in which the burlulipase (or another protein) is heated in the corresponding formulation. In that, the temperature at which the protein is unfolded is detected. It has been shown that a higher unfolding temperature is frequently accompanied by increased thermal stability of the protein. This in turn can require a longer runtime or a higher storage temperature. Details on this analytical method can be found in the article by Youssef and Winter mentioned above.
- A dynamic differential calorimeter of the Nano DSC type of the company TA Instruments with their headquarters in New Castle (Del., USA) was used. Measurements took place with a temperature increase of 1 K/min. A solution of 2 mg/ml of burlulipase in water was prepared. Another solution containing 2 mg/ml of burlulipase and 10 mmol/l of calcium chloride in water was also prepared. The solutions contained no further constituents. Microcalorimetry measurement of the solution of burlulipase in water exhibited a peak at about 73° C. This shows that burlulipase unfolds in an aqueous solution at about 73° C. The corresponding curve for the calcium chloride-containing solution indicated an unfolding temperature of about 88° C., i.e. about 15° C. higher. This is a clear indication that calcium chloride could stabilize burlulipase.
- Aqueous solutions of burlulipase were prepared by dissolving the components in water. 4 solutions were prepared. The pH in all solutions was 7.5. Table 1 shows the compositions of the 4 solutions.
-
TABLE 1 Ingredients Solution 1 Solution 2 Solution 3 Solution 4 Burlulipase [mg/ml] 15 15 15 15 Calcium chloride [mmol] — 1 10 — NaH2PO4 [mmol] — — — 5 Water Residue Residue Residue Residue - The 4 solutions were stored at four different temperatures for a period of several months under otherwise identical conditions. At specific intervals, the activity of the burlulipase was measured. The following tables reflect the results of the tests. All activities are given in percent of the lipolytic activity measured during preparation of the solutions.
-
TABLE 2 Temperature 2 to 8° C. Solution 3 6 9 12 15 No. Start months months months months months 1 100 107.7 102.7 108.7 96.8 107.6 2 100 107.7 105.4 104.l 100.6 114.8 3 100 111.4 109.1 113.2 108.7 109.1 4 100 104.2 97.4 96.0 95.8 104.7 -
TABLE 3 Temperature 25° C. Solution No. Start 3 months 6 months 9 months 12 months 1 100 94.8 84.6 85.9 81.3 2 100 109.4 102.8 101.7 79.5 3 100 113.1 106.4 110.0 107.7 4 100 92.2 83 80.2 76.1 -
TABLE 4 Temperature 30° C. Solution No. Start 3 months 6 months 9 months 12 months 1 100 95.1 83.2 82.6 82.2 2 100 113.6 99.6 105.4 102.0 3 100 120.0 102.5 112.7 110.4 4 100 104.3 85.1 86.8 82.5 -
TABLE 5 Temperature 40° C. Solution No. Start 3 months 6 months 9 months 12 months 1 100 62.3 47.0 not measured 2 100 102.7 84.1 not measured 3 100 105.5 95.2 not measured 4 100 55.2 41.8 not measured - The data shows that calcium ions can stabilize the burlulipase. At a concentration of 10 mmol (solution 3), the effect is clearly more pronounced than at a concentration of 1 mmol (solution 4). Temperatures of 25 to 40° C. correspond to the temperatures to which uncooled medicinal substances are exposed.
- Therefore, the present invention makes it possible to produce liquid pharmaceutical products containing burlulipase. Compared to pharmaceutical products not stabilized with calcium ions, the pharmaceutical products according to the invention are stable enough to ensure a stable supply of the patients with burlulipase. On the other hand, phosphate seems to have a slightly destabilizing effect on burlulipase. In any case, the aqueous solutions according to the invention stabilized by calcium ions are suitable for sequential storage.
- In this experiment, two burlulipases with different 6-deoxy-talane contents were compared. A depletion of the 6-deoxy-talane contained in the burlulipase can be achieved by size exclusion chromatography (SEC). Other methods are also known for this purpose.
- The following table shows investigations on the thermal stability of aqueous solutions of burlulipase, which contain 15 mg/ml of burlulipase. In that, one type of burlulipase contains 30% by weight of 6-deoxy-talane in relation to the dried burlulipase and a second solution contains 1% by weight of 6-deoxy-talane in relation to the dried burlulipase. The pH of the solutions at the beginning of the measurements was 7.5. The measurements were carried out at two different temperatures (25° C. and 40° C.). In addition to the burlulipase, the solutions did not contain any other ingredients. The solutions were stored at two different temperatures for a period of 3 or 6 months, resp., under otherwise identical conditions. After 3 months and also after 6 months, if applicable, the activity of the burlulipase was measured. The following table shows the results of the experiments. All activities are given in percent of the lipolytic activity measured during preparation of the solutions.
-
TABLE 6 Talane content Temperature Start 3 months 6 months 30% by weight 25° C. 100 95.8 86.6 1% by weight 25° C. 100 103.5 94.6 30% by weight 40° C. 100 65.6 — 1% by weight 40° C. 100 79.9 — - As can be seen in the table, the burlulipase solution, which only contains 1% by weight of 6-deoxy-talane, is more stable than the comparative solution with 30% by weight. Therefore, using burlulipase with a low 6-deoxy-talane content in pharmaceutical products is appropriate.
Claims (24)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/868,079 US20230019418A1 (en) | 2017-03-03 | 2022-07-19 | Aqueous solution of burlulipase comprising calcium ions |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102017104480.9A DE102017104480A1 (en) | 2017-03-03 | 2017-03-03 | Aqueous solution of burlulipase comprising calcium ions |
DE102017104480.9 | 2017-03-03 | ||
PCT/EP2018/055380 WO2018158467A1 (en) | 2017-03-03 | 2018-03-05 | Aqueous solution of burlulipase comprising calcium ions |
US201916490550A | 2019-09-01 | 2019-09-01 | |
US17/868,079 US20230019418A1 (en) | 2017-03-03 | 2022-07-19 | Aqueous solution of burlulipase comprising calcium ions |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2018/055380 Continuation WO2018158467A1 (en) | 2017-03-03 | 2018-03-05 | Aqueous solution of burlulipase comprising calcium ions |
US16/490,550 Continuation US11439691B2 (en) | 2017-03-03 | 2018-03-05 | Aqueous solution of burlulipase comprising calciumions |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230019418A1 true US20230019418A1 (en) | 2023-01-19 |
Family
ID=61628318
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/490,550 Active US11439691B2 (en) | 2017-03-03 | 2018-03-05 | Aqueous solution of burlulipase comprising calciumions |
US17/868,079 Pending US20230019418A1 (en) | 2017-03-03 | 2022-07-19 | Aqueous solution of burlulipase comprising calcium ions |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/490,550 Active US11439691B2 (en) | 2017-03-03 | 2018-03-05 | Aqueous solution of burlulipase comprising calciumions |
Country Status (9)
Country | Link |
---|---|
US (2) | US11439691B2 (en) |
EP (1) | EP3423035B1 (en) |
JP (1) | JP6722830B2 (en) |
CN (1) | CN110650726B (en) |
CA (1) | CA3055120C (en) |
DE (1) | DE102017104480A1 (en) |
ES (1) | ES2780386T3 (en) |
PL (1) | PL3423035T3 (en) |
WO (1) | WO2018158467A1 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150367969A1 (en) * | 2014-06-23 | 2015-12-24 | R.P. Scherer Technologies, Llc | Cold Blow-Fill-Seal Packaging System and Process |
US20200009232A1 (en) * | 2017-03-03 | 2020-01-09 | Nordmark Arzneimittel Gmbh & Co. Kg | Orodispersible tablet containing burlulipase and pharmaceutical composition produced therefrom |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4959179A (en) | 1989-01-30 | 1990-09-25 | Lever Brothers Company | Stabilized enzymes liquid detergent composition containing lipase and protease |
ES2125901T3 (en) | 1991-07-01 | 1999-03-16 | Basf Ag | USE OF LIPASES TO OBTAIN MEDICINES. |
DK99492D0 (en) | 1992-08-07 | 1992-08-07 | Novo Nordisk As | NEW ENZYM |
US5968792A (en) * | 1996-12-19 | 1999-10-19 | Henkel Corporation | Calcium activation of lipase enzyme in process of pressure splitting glycerides |
JP4013108B2 (en) | 2001-06-14 | 2007-11-28 | 東洋紡績株式会社 | Method for stabilizing lipase |
DE10235206A1 (en) | 2002-08-01 | 2004-02-19 | Basf Ag | Process for the preparation of (S) -3-methylmino-1- (thien-2-yl) propan-1-ol |
DE102007024539A1 (en) | 2007-05-24 | 2008-11-27 | Fresenius Kabi Deutschland Gmbh | Cap for a container for holding liquids, in particular an enteral nutrient solution and container with such a cap |
DE102009006594A1 (en) * | 2009-01-29 | 2010-08-05 | Nordmark Arzneimittel Gmbh & Co. Kg | Pharmaceutical preparation, useful for the treatment of digestive disorders, cystic fibrosis and pancreatitis, comprises a liquid dosage form of enzymes |
PL2391382T3 (en) | 2009-01-29 | 2014-11-28 | Nordmark Arzneimittel Gmbh & Co Kg | Pharmaceutical preparation comprising lipase of bacterial origin |
WO2011075798A1 (en) * | 2009-12-24 | 2011-06-30 | Bm Gol Pty Ltd | Single-use containers and uses thereof |
US20120220513A1 (en) | 2009-12-29 | 2012-08-30 | Novozymes A/S | Polypeptides Having Detergency Enhancing Effect |
ES2622230T3 (en) | 2011-06-17 | 2017-07-06 | Dalli-Werke Gmbh & Co. Kg | Detergent composition comprising dirt release polymers with improved storage stability |
GB201120368D0 (en) | 2011-11-24 | 2012-01-04 | Sperm Vital As | Methods for the preparation of hydrogels |
US20150132831A1 (en) | 2012-05-16 | 2015-05-14 | Novozymes A/S | Compositions Comprising Lipase and Methods of Use Thereof |
DE102013224250A1 (en) | 2013-11-27 | 2015-05-28 | Henkel Ag & Co. Kgaa | Lipase stabilization in dishwashing detergents |
CN103981168B (en) | 2014-06-05 | 2016-06-22 | 青岛蔚蓝生物集团有限公司 | A kind of compositions improving liquid enzymes stability |
DE202014007438U1 (en) | 2014-09-12 | 2014-12-19 | Berthold Pohl | Liquid application of digestive enzymes |
CN105838509B (en) | 2015-01-16 | 2018-04-24 | 3M创新有限公司 | Enzyme solutions, non-woven fabrics containing enzyme and its preparation method and application |
PL3090638T3 (en) * | 2015-04-20 | 2020-10-19 | Bernd-Michael Löffler | Nutritional supplement to treat signs of vitamin d3 deficiency |
-
2017
- 2017-03-03 DE DE102017104480.9A patent/DE102017104480A1/en not_active Withdrawn
-
2018
- 2018-03-05 ES ES18711043T patent/ES2780386T3/en active Active
- 2018-03-05 CA CA3055120A patent/CA3055120C/en active Active
- 2018-03-05 EP EP18711043.2A patent/EP3423035B1/en active Active
- 2018-03-05 PL PL18711043T patent/PL3423035T3/en unknown
- 2018-03-05 US US16/490,550 patent/US11439691B2/en active Active
- 2018-03-05 JP JP2019547690A patent/JP6722830B2/en active Active
- 2018-03-05 CN CN201880025277.6A patent/CN110650726B/en active Active
- 2018-03-05 WO PCT/EP2018/055380 patent/WO2018158467A1/en active Application Filing
-
2022
- 2022-07-19 US US17/868,079 patent/US20230019418A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150367969A1 (en) * | 2014-06-23 | 2015-12-24 | R.P. Scherer Technologies, Llc | Cold Blow-Fill-Seal Packaging System and Process |
US20200009232A1 (en) * | 2017-03-03 | 2020-01-09 | Nordmark Arzneimittel Gmbh & Co. Kg | Orodispersible tablet containing burlulipase and pharmaceutical composition produced therefrom |
Non-Patent Citations (2)
Title |
---|
Khattabi et al., JBC, 2000, 275(35):26885-26891. * |
Somaraju et al. PANCREATIC ENZYME REPLACEMENT FOR PEOPLE WITH CYSTIC FIBROSIS; Cochrane Database of Systematic Reviews, Issue 8, Art. No. CD008227, pp. 1-73 (Year: 2020) * |
Also Published As
Publication number | Publication date |
---|---|
CN110650726B (en) | 2021-10-08 |
WO2018158467A1 (en) | 2018-09-07 |
EP3423035A1 (en) | 2019-01-09 |
PL3423035T3 (en) | 2020-06-01 |
US11439691B2 (en) | 2022-09-13 |
JP2020509055A (en) | 2020-03-26 |
EP3423035B1 (en) | 2020-01-01 |
JP6722830B2 (en) | 2020-07-15 |
ES2780386T3 (en) | 2020-08-25 |
CA3055120C (en) | 2021-01-26 |
CA3055120A1 (en) | 2018-09-07 |
DE102017104480A1 (en) | 2018-09-06 |
US20200009233A1 (en) | 2020-01-09 |
CN110650726A (en) | 2020-01-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7448507B2 (en) | Methods and compositions for CNS delivery of arylsulfatase A | |
US9770410B2 (en) | Methods and compositions for CNS delivery of arylsulfatase A | |
CN100448482C (en) | Freeze dried HGF preparations | |
JP5253501B2 (en) | Stabilized thrombin composition | |
BRPI0813948B1 (en) | PHARMACEUTICAL LIQUID COMPOSITION OF BOTULIN TOXIN WITH IMPROVED STABILITY | |
US20200237883A1 (en) | Stable formulations for cns delivery of arylsulfatase a | |
MX2011004861A (en) | Factor viii formulations. | |
JPH07173076A (en) | Preparation of stabilized human tissue plasminogen activatorcomposition | |
KR20170096178A (en) | Pharmaceutical composition comprising plasminogen and uses thereof | |
JP2005538068A (en) | Solution containing high concentration of human growth hormone (hGH) and phenol | |
BR112012027361A2 (en) | stable medium / cd-rap formulation. | |
AU2013355046A1 (en) | Methods and compositions for intrathecally administered treatment of mucupolysaccharidosis Type IIIA | |
US20170266221A1 (en) | Compositions and Methods For Treating Joints | |
US11439691B2 (en) | Aqueous solution of burlulipase comprising calciumions | |
US11464834B2 (en) | Orodispersible tablet containing burlulipase and pharmaceutical composition produced therefrom | |
AU2012358223A1 (en) | Treatment of cognitive impairment of Hunter syndrome by intrathecal delivery of iduronate-2-sulfatase | |
CN104023742A (en) | Improved formulations of recombinant human bile salt-stimulated lipase | |
CA2950392A1 (en) | Lyophilized formulation of tat-nr2b9c with acetylation scavenger | |
EP3287140B1 (en) | Nerve growth factor composition and powder injection | |
US9409662B2 (en) | Formulations of albu-BChE, preparation and uses thereof | |
EP3287141B1 (en) | Nerve growth factor composition and injection powder | |
EP3325000A1 (en) | Treatment of cognitive impairment of mucopolysaccharidosis type iiia by intrathecal delivery of heparan n-sulfatase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: NORDMARK PHARMA GMBH, GERMANY Free format text: CHANGE OF NAME;ASSIGNOR:NORDMARK ARZNEIMITTEL HOLDING GMBH & CO.;REEL/FRAME:060551/0441 Effective date: 20210723 Owner name: NORDMARK ARZNEIMITTEL GMBH & CO. KG, GERMANY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FUHRHERR, RICHARD;MULLER-LUCKS, ANNIKA;RUTZEL, KATHARINA;AND OTHERS;SIGNING DATES FROM 20190920 TO 20191121;REEL/FRAME:060551/0206 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: ADVISORY ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |